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Abstract
Background: World Health Organization rehydration management guidelines (plan C) for severe dehydration are
widely practiced in resource-poor settings, but never formally evaluated in a trial. The Fluid Expansion as a Supportive
Therapy trial raised concerns regarding the safety of bolus therapy for septic shock, warranting a formal evaluation of
rehydration therapy for gastroenteritis.
Methods: A multi-centre open-label phase II randomised controlled trial evaluated two rehydration strategies in 122
Ugandan/Kenyan children aged 60 days to 12 years with severe dehydration secondary to gastroenteritis. We compared
the safety and efficacy of standard rapid rehydration using Ringer’s lactate (100 ml/kg over 3 h (6 h if < 1 year),
incorporating 0.9% saline boluses for children with shock (plan C) versus slower rehydration: 100 ml/kg Ringer’s lactate
over 8 h (all ages) without boluses (slow: experimental). The primary outcome was the frequency of serious adverse
events (SAE) within 48 h including cardiovascular, respiratory and neurological complications. Secondary outcomes
included clinical, biochemical and physiological measures of response to treatment by intravenous rehydration.
Results: One hundred twenty-two eligible children (median (IQR) age 8 (6–12) months) were randomised to plan C
(n = 61) or slow (n = 61), with two (2%) lost to follow-up at day 7). Following randomisation mean (SD) time to start
intravenous rehydration started was 15 min (18) in both arms. Mean (SD) fluid received by 1 hour was greater in plan C
(mean 20.2 ml/kg (12.2) and 33.1 ml/kg (17) for children < 1 year and >− 1 year respectively) versus 10.4 ml/kg (6.6) in
slow arm. By 8 hours volume received were similar mean (SD) plan C: 96.3 ml/kg (15.6) and 97.8 ml/kg (10.0) for children
< 1 and ≥ 1 year respectively vs 93.2 ml/kg (12.2) in slow arm. By 48-h, three (5%) plan C vs two (3%) slow had an SAE
(risk ratio 0.67, 95% CI 0.12–3.85, p = 0.65). There was no difference in time to the correction of dehydration (p = 0.9) or
time to discharge (p = 0.8) between groups. Atrial natriuretic peptide levels rose substantially by 8 hours in both arms,
which persisted to day 7. Day 7 weights suggested only 33 (29%) could be retrospectively classified as severely
dehydration (≥ 10% weight loss).
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Conclusion: Slower rehydration over 8 hours appears to be safe, easier to implement than plan C. Future large trials with
mortality as the primary endpoint are warranted.
Trial registration: ISRCTN67518332. Date applied 31 August 2016.
Keywords: Rehydration, Severe dehydration, Intravenous fluids, African children, Clinical trial
Background
Worldwide, an estimated 2.5 billion cases of acute gastro-
enteritis occur annually in children under 5 years. In this
age group, gastroenteritis is the second biggest cause of
mortality (after acute respiratory illnesses) [1, 2]. The vast
majority of deaths occur in low resource settings in South
Asia and sub-Saharan Africa. A large case-control study,
Global Enteric Multicentre study of gastroenteritis
(GEMS), conducted in Africa and Asia showed that chil-
dren with moderate/severe gastroenteritis seeking care at
health centres are 8.5 times more likely to die than non-
gastroenteritis controls [3, 4]. A third of the fatalities
occurred < 7 days following enrolment—indicating that
current treatment strategies may not be working in prac-
tice and/or are poorly implemented [5].
The World Health Organization (WHO) has produced
guidance on the management of dehydration in children
with diarrhoea, largely based on expert opinion [6, 5]. In
children (without severe malnutrition), oral rehydration so-
lution (ORS) is recommended for children with diarrhoea
with some dehydration, defined as two or more of the fol-
lowing: restlessness/irritability, sunken eyes, drinks eagerly/
thirsty and/ or skin pinch goes back slowly (plan B). Intra-
venous fluids are recommended for resuscitation of chil-
dren with severe dehydration, defined as the presence of
two or more of the following clinical features: sunken eyes,
skin pinch goes back very slowly ≥ 2 seconds (s), lethargy
and/or inability to drink (under the protocol called ‘plan
C’), using 100 ml/kg of Ringer’s lactate or 0.9% saline [6].
This is the approximate volume estimated to have been lost
in children with 10% dehydration and is recommended to
be given over 3 h (or 6 h in children < 1 year). Plan C con-
sists of two steps in which the volume and rate of infusion
are different and also differ by age group (< 1 year and ≥ 1
year). In Step 1 30 ml/kg over 30min (or 1 h if < 1 year)
and then in Step 2 70 ml/kg over 2.5 h (or 5 h if < 1 year).
For children presenting with shock (defined as the presence
of all three of weak and fast pulse, temperature gradient
and capillary refilling time > 3 s), WHO also recommends
initial fluid boluses given for shock (i.e. up to 3 boluses of
20 ml/kg of normal (0.9%) saline given as rapidly as pos-
sible) followed directly by Step 2, i.e. 90–130 ml/kg. These
management guidelines are recommended in resource-
poor settings, despite no formal testing in a clinical trial [7].
A review of the evidence underpinning WHO management
guidelines in 2012, with regard to shock and rehydration
management, focused principally on the type of fluid for re-
suscitation but did not consider the rate or volume [5].
Evidence from trials, reviews and audits
In the phase III FEAST randomised controlled trial, fluid
bolus therapy was compared with maintenance fluids in
children with signs of shock and febrile illness, which
showed 3.3% higher absolute mortality in children rando-
mised to fluid bolus therapy compared with maintenance
only (control). A subsequent analysis of the terminal clin-
ical event revealed that the excess mortality in children
enrolled in the fluid bolus arms was attributable to cardio-
vascular collapse rather than neurologic or respiratory
events [8]. Children with acute gastroenteritis, severe mal-
nutrition and fluid loss due to other causes were excluded
from the trial [9]. The FEAST trial also raised concerns re-
garding the safety of rapid intravenous rehydration therapy
in other settings and other common illnesses requiring ag-
gressive fluid such as acute gastroenteritis.
A systematic review of intravenous rehydration world-
wide found only 3 trials (n = 464) comparing rates of rehy-
dration; none were conducted in resource-poor settings
[10]. There were no deaths in any of the reported trials but
a pooled analysis suggested longer time-to-discharge and
higher readmission rates in the rapid rehydration arms [10,
7]. Emerging data on outcomes from acute gastroenteritis
across a network of Kenya hospitals involving 1211 children
with severe dehydration who were managed with the
current WHO plan C found that in-hospital mortality was
8% in those with severe dehydration and increased to 34%
if this was complicated by shock [11]. In summary, the
current evidence base for plan C has been judged to be of
very low quality as it relies on expert option.
Given the information provided by the FEAST trial
and the high early mortality for acute gastroenteritis
with severe dehydration, we conducted a phase II trial
investigating the impact of different rates of rehydration
on clinical and physiological outcomes.
Methods
Study design and treatment protocol
We conducted a multi-centre, open-label phase II rando-
mised controlled trial comparing WHO standard (fast or
aggressive) versus slow (experimental) intravenous rehydra-
tion of children admitted to hospital with gastroenteritis
and severe dehydration. Eligible children from three clinical
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centres in Eastern Uganda (Mbale and Soroti Regional
Referral Hospitals) and Kenya (Kilifi County Hospital) were
randomly assigned on admission to hospital (ratio 1:1) to
receive either (1) WHO plan C, 100ml/kg over 3 (≥ 1 year)
or 6 h (< 1 year), plus additional boluses for treatment of
shock, or (2) slower rehydration, 100ml/kg over 8 h regard-
less of age, without fluid boluses. To assist with the accur-
ate administration of intravenous fluid volumes and rates,
the study used gauged burettes and infusion sets to ensure
adherence to the protocol. At the time of the trial, Kenya
had introduced rotavirus vaccination for young infants but
Uganda had not. During the period of study, there were no
reported epidemics of cholera in either location.
Study population
Screening procedures
We aimed to enrol 120 children, aged 60 days to 12 years,
with severe dehydration secondary to gastroenteritis at ad-
mission to the paediatric ward. Dedicated trial clinicians
and nurses screened potentially eligible children. Children
were eligible if they had a history of gastroenteritis (> 3
loose stools/day) and signs of severe dehydration (as per
WHO definition, two or more of the following: unable to
drink or AVPU <A, with sunken eyes and reduced skin
pinch (> 2 s) and/or an inability to take or retain oral
fluids), with or without shock. Hypovolaemic shock was
defined by the recent 2016 WHO ETAT criteria, a patient
with all of the following: cold peripheries with a weak and
fast pulse (rate not specified) and a capillary refill time
more than 3 s. We excluded children with severe malnu-
trition (kwashiorkor or MUAC < 11.5 cm), diarrhoea last-
ing more than 14 days, known congenital or rheumatic
heart disease and absence of a parent or guardian willing/
able to give consent.
Outcome measures
The primary outcome was the frequency of fluid-related
serious adverse events (including mortality, cardiovascu-
lar collapse, suspected raised intracranial pressure, pul-
monary oedema) within 48 h. Secondary outcomes
included time to correct signs of severe dehydration,
time to tolerate oral fluids/feeds and time to discharge,
dysnatraemia (defined as < 135 mmol or > 145 mmol/L)
[7] at 8 h and readmission to hospital (within 7 days
post-discharge).
Study procedures
Screening and randomisation
Children with suspected severe dehydration based on
presenting symptoms were clinically assessed for severity
and other exclusion criteria. Once eligibility was con-
firmed, authorised trial staff approached parents/guard-
ians to invite their child to take part in the trial. Where
prior written consent from parents/legal guardians could
not be obtained, ethics committees approved parental
verbal assent and deferred written informed consent as
soon as practicable [12]. Otherwise, informed written
consent was obtained from parents or guardians before
randomisation. The randomisation list and envelopes
were prepared by an independent data manager in
KWTP Kilifi. The lists were not available to investigators
and were stratified by clinical centre. The schedule for
each centre contained a list of trial numbers and the
randomly allocated intervention. The treatment alloca-
tion (plan C versus slow intravenous rehydration) was
kept in numbered, sealed opaque envelopes. The cards
were numbered consecutively and opened in numerical
order.
Sample size
A formal sample size was not calculated. We aimed to
study 120 children (60 in each arm) to provide sufficient
pilot data (clinical and physiological) on the main out-
comes given the timeframe of the study whilst balancing
against exposing children to a therapeutic intervention
(rate) for which there are limited data. We have used
similar sample sizes in the past in fluid resuscitation
studies (comparing rates and different types of fluids
that informed the design of FEAST) [13, 14].
Clinical monitoring and study assessments
Following consent and randomisation, the patients were
commenced on the intravenous rehydration protocol as de-
tailed in Table 1. Clinical and haemodynamic responses
were monitored at 1, 2, 4, 8, 12 h and then daily until dis-
charge. At each clinical assessment, children were assessed
for pre-specified serious adverse events of interest (new-on-
set seizures or worsening conscious level (neurological),
signs of pulmonary oedema, cardiac failure or cardiovascu-
lar collapse post-randomisation). Blood samples were
routinely collected at admission, 8 h and 24 h and stored
for future batch processing. This included standard bio-
chemistry, cardiac biomarkers (cardiac troponin I (cTnI); A
type and B type natriuretic peptides (ANP and BNP re-
spectively)) at admission, 8 h and 24 h. Stool samples were
not collected so no data are available on the pathogenic
aetiology of gastroenteritis in the trial population.
Cardiac biomarker methodology
Blood was collected in tubes with ethylene diamine tetraa-
cetic acid (EDTA) anticoagulant, centrifuged at 4 °C and a
volume of 500 μL aliquoted and frozen at − 800. Plasma
samples were batch-processed and cardiac biomarkers
quantified using standard human enzyme linked immuno-
sorbent assays (ELISAs) (ANP and BNP, Thermofisher
Scientific and cTnI, Abcam®).
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Serious adverse events
Serious adverse events (SAE) were reported on a
standardised SAE form and sent to the Clinical Trials
Facility, Kilifi, Kenya, and to local ethics board and
were monitored against source documents by inde-
pendent monitors. The SAE forms the local clinician
SAE monitor blinded all SAES to intervention strat-
egy before sending these to the Endpoint Review
Committee (ERC) who reviewed all deaths, neurologic
events and other SAEs blinded to treatment arm. The
classification of suspected pulmonary oedema and car-
diovascular collapse used the same definitions as re-
ported in FEAST paper reporting modes of death [8].
Further management
Following correction of dehydration (based on a review
of WHO clinical signs and observations), children were
assessed for their ability to take oral rehydration or
feeds. Children who were able to take and retain oral
fluids/feeds and who were in neutral or marginally posi-
tive fluid balance (both input and output were mea-
sured) were considered as satisfactorily rehydrated. For
the purposes of protocol adherence, each child com-
pleted their allocated intravenous fluid hydration regi-
men regardless of when they were satisfactorily
rehydrated, as WHO recommends to complete rehydra-
tion first before re-evaluating [4]. Once able to tolerate
oral fluids, children were offered oral rehydration fluids
alongside their intravenous rehydration regimen. Each
child had an input-output fluid monitoring chart, which
included urinary catheter volumes (where parents con-
sented) and diaper weights, designed to document the
volumes that children in both arms were drinking and
retaining as well as defining clinical end-points. If a child
developed suspected signs of fluid overload, intravenous
Table 1 Trial treatment arms
Age WHO Plan C Slow arm
No shock With WHO shock* No shock With shock
< 12 months Step 1
30 ml/kg over 1 h
Step 2
70 ml/kg over 5 h
Resuscitate:
Up to 3 × 20ml/kg bolus then to step 2
70 ml/kg over 5 h
100 ml/kg over 8 h 100 ml/kg over 8 h with
No additional boluses
> 12 months Step 1
30 ml/kg over 30 min
Step 2
70 ml/kg over 2.5 h
Resuscitate:
Up to 3 × 20ml/kg bolus then to step 2
70 ml/kg over 2.5 h
100 ml/kg over 8 h 100 ml/kg over 8 h
No additional boluses
*Shock defined as presence of all three of the following: Weak and fast pulse, temperature gradient and prolonged capillary refill time > 3 s (10)
Fig. 1 Trial flow
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fluids were stopped and if there were signs of pulmonary
oedema, clinicians were permitted to administer intra-
venous furosemide (1–2 mg/kg) and supplemental oxy-
gen (if saturations < 90% by pulse oximetry). When
stable, further fluid management was administered orally
(or via nasogastric tube if the child was unable to take
fluids orally). If there were ongoing significant gastro-
intestinal fluid losses with persisting dehydration, the
protocol permitted one repeat of rehydration regime as
per their randomised arm. Only after this were clinicians
free to personalise additional fluid management to take
account of input/output.
Children returned for follow-up on day 7 for a clinical as-
sessment, weight and vital sign observations, a further blood
sample (for biochemistry and cardiac biomarkers) and urine
sample for urinary electrolytes. These assessments of hydra-
tion (in children without any on-going losses or intercurrent
illness) served to validate inpatient assessments.
Data management and statistical analysis
All clinical and laboratory data was recorded in case report
forms (CRFs) with a unique identifier. Data was entered
onto Open Clinica. All statistical analyses were documented
Table 2 Baseline characteristics
WHO plan C GASTRO slow Total
Female, n (%) 23 (38) 27 (44) 50 (41)
Age (months), median (IQR) 9 (6–12) 8 (6–12) 8 (6–12)
Weight (kg), median (IQR) 7.7 (6.8, 8.3) 7.3 (6.8,8.3) 7.5 (6.7–8.3)
Axillary temperature (°C), median (IQR) 37.6 (37.0, 38.2) 37.8 (37.2, 38.3) 37.7 (37.0, 38.2)
< 36, n (%) 1 (2) 1 (2) 2 (2)
> 37.5, n (%) 32 (52) 37 (61) 69 (57)
Sunken eyes, n (%)
Slightly sunken 17 (28) 18 (30) 35 (29)
Very sunken 44 (72) 42 (69) 86 (70)
Decreased skin turgora, n (%) 32 (52) 34 (56) 66 (54)
Heart rate, median (IQR) 145.0 (138.5, 159.0) 149.5 (140.5, 160.5) 148 (139, 160)
Bradycardia (< 80 bpm), n (%) 0 (0) 0 (0) 0 (0)
Severe tachycardiab, n (%) 7 (11) 11 (18) 18 (15)
Systolic blood pressure, median (IQR) 90 (85, 95) 89 (85, 96.5) 89 (85, 96)
Moderate hypotension, n (%)c 2 (3) 5 (8) 7 (6)
Severe hypotension, n (%)d 1 (2) 0 (0) 1 (1)
Capillary refill time, median (IQR) 1 (1, 1) 1 (1, 1) 1 (1, 1)
≥ 3, n (%) 5 (8) 3 (5) 8 (7)
No. with weak pulse, n (%) 6 (10) 7 (11) 13 (11)
No. with temperature gradient, n (%) 11 (18) 10 (16) 21 (17)
Respiratory rate, median (IQR) 40 (37, 48) 44 (40, 50) 43 (38, 49)
Fast breathing, n (%) 2 (3) 3 (5) 5 (4)
Respiratory distress, n (%) 5 (8) 9 (15) 14 (11)
Oxygen saturation, median (IQR) 98 (97, 99) 98 (97, 98) 98 (97, 99)
Conscious level, n (%)
Alert 12 (20) 16 (26) 28 (23)
Lethargic 35 (57) 30 (49) 65 (53)
Prostrate 13 (21) 13 (21) 26 (21)
Coma 1 (2) 2 (3) 3 (2)
No. with fits or convulsions, n (%) 1 (2) 0 (0) 1 (1)
aRecoil from skin pinch > 2 s
bDefined as heart rate > 180 for age < 12 months; > 160 for age 12–60 months; > 140 for age ≥ 60 months
cModerate Hypotension defined as: if < 12 months = 50-75 mmHg; 12 months to 5 yrs = 60-75 mmHg; > 5 yrs = 70-85mmHg
dSevere hypotension defined as: if < 12 months ≤ 50mmHg; 12 months to 5 yrs ≤ 60mmHg, > 5 yrs ≤ 70mmHg
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a priori in the statistical analysis plan and were undertaken
using intention-to-treat. The risk ratio and risk difference
were calculated to compare proportions reaching the pri-
mary outcome between arms. Time-to-event secondary
outcomes were analysed using Kaplan Meier plots and log
rank tests. Proportions of children with dynstraemia at 8 h
were compared with a χ2 test.
Results
Study patients
One hundred twenty-two children were randomised from 9
January 2017 to 15 February 2018 across the three sites (69
at Mbale, 45 at Soroti and 8 at Kilifi), with 61 allocated to
each arm. All children included in the trial met the eligibil-
ity criteria (trial flow: Fig. 1). Baseline characteristics were
broadly balanced between arms, although some differences
were present as expected given small sample size. The me-
dian age was 8months (IQR 6–12); 70% were under 12
months of age. On admission, 69 children (57%) were fe-
brile (axillary temperature > 37.5C), 86 (70%) had very
sunken eyes and 66 (54%) had severely decreased skin tur-
gor. Most had altered conscious level with only 23% of
patients reported as alert, 26 (21%) were prostrated and 3
were comatosed and 11% (14) had signs of respiratory
distress (Table 2).
Children at admission had evidence of markedly de-
ranged biochemistry (Table 3). Overall, 24/103 (23%) had
hyponatraemia (sodium < 135mmol/L); 38 (37%) had
hypernatremia (sodium > 145mmol/L) of whom 27 (26%)
had severe hypernatraemia (sodium > 150mmol/L). As ex-
pected, there was a significant number of children with
high urea, 52 (50%), and/or high creatinine (> 74mmol/L).
After admission, only one child (plan C) developed
hypoglycaemia (glucose < 3 mmol/L) requiring correction.
Adherence to protocol
In the plan C arm, 2 children met the criteria for shock on
admission and received boluses (1 child had one bolus of
20 ml/kg and 1 child had 2 × 20 ml/kg boluses) and 1
child in the slow arm met the shock criteria and did not
receive a bolus (Table 4). The time taken to start fluids
Table 3 Admission, 8 hour and 24 hour biochemistry
Plan C GASTRO slow Total
Admission laboratory
N 53 50 103
Sodium, median (IQR) 139 (132, 149) 143 (137, 156) 142 (136, 154)
Hyponatremia (< 135mmol/L), n (%) 16 (30) 8 (16) 24 (23)
Hypernatremia (> 145mmol/L), n (%) 15 (28) 23 (46) 38 (37)
Severe hypernatraemia > 150mol/L, n (%) 11 (21) 16 (32) 27 (26)
Hypokalaemia (< 3.5 mmol/L), n (%) 11 (21) 8 (16) 19 (18)
High creatinine (> 74mmol/L), n (%) 11 (21) 12 (24) 23 (23)
High urea (> 6.4 mmol/L), n (%) 26 (49) 26 (52) 52 (50)
Glucose, median (IQR) 5.4 (4.9, 6.3) 5.3 (4.4, 6.9) 5.4 (4.7, 6.8)
Lactatea, median (IQR); N 1.2 (1.0, 2.1); 29 1.3 (1.1, 1.7); 27 1.3 (1.0, 1.7); 56
High lactate > 3 mmol/l, n (%) 4 (14) 0 (0) 4 (7)
At 8 hours
N 50 52 102
Sodium, median (IQR) 142 (135, 147) 142 (138, 148) 142 (136, 148)
Hyponatremia (< 135mmol/L), n (%) 12 (24) 6 (12) 18 (18)
Hypernatremia (> 145mmol/L), n (%) 17 (34) 19 (37) 36 (35)
Severe hypernatraemia > 150mol/L, n (%) 7 (14) 10 (19) 17 (17)
At 24 hours
N 41 45 86
Sodium, median (IQR) 142 (138, 154) 143 (138, 156) 143 (138, 155)
Hyponatremia (< 135mmol/L), n (%) 7 (17) 5 (11) 12 (14)
Hypernatremia (> 145mmol/L), n (%) 16 (39) 18 (40) 34 (40)
Severe hypernatraemia > 150mol/L, n (%) 12 (29) 16 (36) 28 (33)
aSoroti sites were unable to do lactate tests
Houston et al. BMC Medicine          (2019) 17:122 Page 6 of 14
was similar in both arms with a mean 15min (sd 18) from
randomisation. At 1 h, children < 1 year had received a
mean 20.2 ml/kg (sd 12.2) and children ≥ 1 year received
33.1 ml/kg (sd 17) in plan C arm and children in the slow
arm received a mean 10.4 ml/kg (sd 6.6). By 8 h, the mean
volume received was very similar between arms (96.3 ml/
kg (sd 15.6) children < 1 year and 97.8 ml/kg (sd 10.0) for
children ≥ 1 year in plan C, and 93.2 ml/kg (sd 12.2) in
slow arm) (Table 2, Fig. 2). Non-adherence to protocol oc-
curred in one child in the plan C arm who died before
receiving the total amount of fluids and 2 patients in the
slow arm received their fluids over a longer period of time
Table 4 Volumes of fluid received during the first 12 h of admission
WHO plan C GASTRO slow
Under 1 year 1 year or over All ages
Patients, n 42 19 61
Number of patients in shock 1 1 1
Number of patients who received initial bolus 1 1 0
Total volume of bolus fluid received Mean 20 40 0
Total volume of fluid received (ml/kg) up to:
30 min Mean (sd) 10.2 (6.1) 22.1 (11.1) 5.4 (3.5)
Median (IQR) 14.9 (7.5, 15) 30 (15, 30) 6.2 (3.2, 6.3)
1 h Mean (sd) 20.2 (12.2) 33.1 (17.0) 10.4 (6.6)
Median (IQR) 30 (15, 30) 30 (30, 44) 12.5 (6.3, 12.6)
3 h Mean (sd) 49.3 (12.5) 78.8 (23.0) 33.3 (8.4)
Median (IQR) 44.1 (44, 58) 86.1 (58, 100) 37.4 (25.1, 37.6)
6 h Mean (sd) 90.5 (16.7) 95.8 (11.8) 70.3 (11.9)
Median (IQR) 100 (86, 100) 100 (100, 100) 74.8 (62.9, 75.2)
8 h Mean (sd) 96.3 (15.6) 97.8 (10.0) 93.2 (12.2)
Median (IQR) 100 (100, 100) 100 (100,100) 100 (87.7100)
12 h Mean (sd) 98.9 (16.2) 100.7 (10.9) 98.7 (8.6)
Median (IQR) 100 (100, 100) 100 (100, 100) 100 (100, 100)
Fig. 2 Mean volumes of fluid received during the first 12 h from randomisation. Mean volume (in millilitres per kilogramme) and 95% CI calculated at each
time point (30 min, 1 h then hourly until 12 h)
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(24 and 28 h respectively) than described in the protocol.
An additional 2 patients (one in each arm) had an incom-
plete recording of the fluid volume received.
Primary outcomes
In the plan C arm, 3 patients (5%) had a serious adverse
event (two cardiovascular collapse (resulting in death)
and one status epilepticus (resolved) within 48 h of
randomisation compared with 2 (3%) (suspected pul-
monary oedema and cardiovascular collapse (both
resulting in death) in the slow arm (risk ratio 0.67, (95%
CI 0.12, 3.85); risk difference − 1.6%, (95% CI − 8.7%,
5.4%); p = 0.65). There was 1 additional SAE (convul-
sions) in the slow arm that occurred at 101 h from ran-
domisation, which resolved without other complications
(Table 5). Only one of the SAEs was judged to be prob-
ably related to the study fluid (in the plan C arm), with
the other 5 unlikely to be related (clinical details sum-
marised in Table 6). Overall mortality (to hospital dis-
charge) was 4/122 (3.3%).
Secondary outcomes
The median time to tolerate fluids was 6.5 h (IQR 2.2–
36.3) in the slow arm and 11.9 h (IQR 4.0–30.6) in plan C
arm; this difference was not statistically significant
(p = 0.27). There was no evidence of a difference in time
to correction of dehydration (p = 0.9) nor time to dis-
charge (p = 0.8) (Fig. 3). Only 54/122 patients (44%) had a
record of passing urine within 24 h of starting fluids, likely
due to a large number of parents not consenting for their
child to be catheterised. Using the available data, there
was no evidence of a difference in time to pass urine
x(p = 0.57) (Fig. 3). There were no readmissions within 7
days in either treatment arm. Vital status at 7 days was
ascertained on 60 children in the plan C arm and 59 in
the slow arm (Fig. 1). Dysnatraemia at 8 h was present in
29 (58%) children in the plan C arm compared to 25
(48%) children in the slow arm (p = 0.32) (Table 3).
Table 5 Serious adverse events recorded during the trial
WHO plan C
n = 61
GASTRO slow
n = 61
Number of SAEs 3 (4.9%) 3 (4.9%)
Outcome of SAE
Resolved 1 1
Died 2 (3.3%) 2 (3.3%)
Relationship to study fluid
Unlikely to be related 2 3
Probably related 1 0
Nature of event
Pulmonary oedemaa 0 1
Cardiovascular collapseb 2 1
Other:
Status Epilepticus (child with severe
malarial anaemia)
1 0
Convulsions 0 1
aDevelopment of hypoxia (PaO2 < 90%) with chest signs (crepitations
or indrawing)
bSigns of shock at the point of demise: severe tachycardia or bradycardia plus
one of prolonged CRT > 2 s, cold peripheries or low systolic blood pressure
Table 6 Serious adverse events: clinical details
Number Site Arm Event type Outcome Relationship* Additional details
GAS230 Mbale Plan C Convulsions Resolved Unlikely Lethargic at admission and suffered repeated seizures/status (controlled by IV
diazepam) after admission leading to worsening conscious level. Previous
history of seizures prior to admission (in this illness). Severe malaria anaemia:
received 1 unit of whole blood.
GAS263 Mbale Slow Suspected
Pulmonary
oedema
Fatal Unlikely Severe pneumonia and gastroenteritis. Left-sided pleural effusion on x-ray.
Lethargic at admission. Had worsening difficulty in breathing needing
supplemental oxygen. Died about 36 h into admission.
GAS002 Kilifi Plan C Cardiovascular
collapse/heart
failure
Fatal Probable Comatose, hypoglycaemic and in shock at admission. Fluid boluses x 2:
post-resuscitation echo showed “worsening biventricular function, tricuspid
regurgitation and right atrial enlargement” treated with frusemide intravenously.
Died 13 h into admission: cause of death: heart failure.
GAS003 Kilifi Plan C Cardiovascular
collapse
Fatal Unlikely Severe pneumonia and gastroenteritis and had prolonged capillary refilling and
a weak pulse at admission. Required supplemental oxygen at admission but did
get a bolus. Died 1-h post-admission following cardiovascular collapse. Blood
culture: Haemophilus influenzae.
GAS004 Kilifi Slow Convulsions Resolved Unlikely Comatose and hypoglycaemic at admission. Suffered seizures on day 3 of
admission. Admission history suggested seizures (in this illness) prior to
admission. Seizures were controlled with I.V phenobarbitone
GAS007 Kilifi Slow Cardiovascular
collapse
Fatal Unlikely Comatose at admission, very sick needing supplemental oxygen (saturations
52%) by mask and had hepatomegaly 4 cm BCM. Suffered seizures following
admission which were controlled with I.V phenytoin. Died about 10 h into
admission following cardiac arrest that was preceded by respiratory arrest.
*By attending clinician
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Cardiac biomarkers
We also aimed to evaluate the effects of volume loading
(stretch) and myocardial injury by measuring cardiac
troponin [15] and natriuretic peptides [16, 17]. Figure 4
summarises the median and interquartile ranges of each
of the three cardiac biomarkers by randomisation arm
and over time (0, 8, 24 h and 7 days). BNP levels were
slightly elevated in more than half of the children in
both groups at admission, returning to normal levels by
8 h. Cardiac troponin levels increased from admission
and remained raised at 8 h, 24 h and day 7, but were still
mainly within physiological limits. From relatively nor-
mal range at admission, there were substantial ANP
levels rises at 8 h in both arms, which persisted to day 7.
Overall, there were no significant differences in the ANP
distribution at 8 h (Kolmogorov-Smirnov tests p = 0.6).
We were not able to perform non-invasive monitoring
of myocardial function.
Assessment of degree of dehydration
At day 7, we reviewed the weight of 115 children and
compared this to weight (using the same Salter weighing
scales on both occasions) at admission (pre-rehydration)
to retrospectively assess the degree of dehydration at pres-
entation (Tables 7 and 8). Day 7 weight was chosen owing
the previous problems with poor reliability of an in-
patient assessment of weight (see the ‘Discussion’ section).
Overall, day 7 weights suggested that 52 (45%) had be-
tween 0 and 5% dehydration at admission and only 33
(29%) could be retrospectively classified as severely dehy-
dration (≥ 10%). There were few differences in the number
of features of dehydration in the 0–5% and 5–10%
Fig. 3 Secondary outcomes
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a)
c)
b)
Fig. 4 Cardiac biomarkers over time in children receiving plan C and slow rehydration. a Atrial natriuretic peptide (ANP). b Brain natriuretic peptide (BNP).
c Cardiac troponin (cTrp)
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categories and only marginally more signs of dehydration
in those with severe dehydration (as indicated by ≥ 10%
percentage change in weight at day 7).
Discussion
In this clinical trial involving 122 children with severe de-
hydration due to gastroenteritis, we have shown that a
simpler protocol involving slower rehydration with
100 ml/kg over 8-h irrespective of age was as safe as the
2-stage age-specific WHO plan C protocol. Correction of
dehydration and time to tolerate oral fluids and time to
discharge was similar in both arms. Overall, mortality in
this phase II trial was substantially lower (3.3%) than pre-
vious reports [4, 11] and few other adverse events were
recorded.
One of the additional objectives of the trial was to assess
adherence to the rehydration protocol and other challenges
for implementation rehydration. Whilst current manage-
ment guidelines (WHO plan C) are thought to be widely
practiced in African hospitals, it became apparent when
conducting the training for the clinical trial that clinicians
prior to the trial were not routinely able to adhere to plan
C for a number of reasons. First, the administration of ac-
curate volume and rates of infusion were found to be chal-
lenging to hospitals where gauged burettes or infusion sets
are routinely unavailable. Second, the two-step plan C
involving a fast infusion followed by slower intravenous re-
placement at two different rates and volumes for two age
groups were confusing and thus difficult to recall and
implement accurately in practice [18]. Finally, the WHO
treatment guideline for the child with severe dehydration
presenting with shock [6] is rather opaque on whether fluid
boluses (20 ml/kg of normal saline given as fast as possible
and repeated up to two times if shock persists) are given in
addition to rehydration (thus, the maximum volume a child
could receive would be 160 ml/kg) in 4–6 h. We found ini-
tially navigating and executing the plan C guideline a chal-
lenge to teach and implement, yet the trial teams, as a
result of recurrent training throughout the trial, were able
to demonstrate adherence to the guideline in the study
arm.
In the design of the trial, when considering secondary
outcomes, we aimed to use guideline recommendations for
assessing the reversal of dehydration. First, we aimed to
check on whether the clinical signs for severe dehydration
accurately predict the degree of dehydration. We based this
on the gold standard looking at the percentage change in
weight from admission to day 7, rather than weight at dis-
charge since this time point has not been reliable previously
[19, 20]. We found that although the trial was targeting
children that were assumed to have 10% or more dehydra-
tion, our data suggests this was present in only 33 (29%),
with 30 (26%) having a deficit of > 5- < 10% and nearly half
with only modest deficit (1–5%). There have been several
systematic reviews covering the issue of the specificity of all
the available dehydration scores; nearly all perform poorly
in practice [21] including the WHO scoring. Of note during
initial rehydration, at 8-h most children remained clinically
dehydrated, based on the same signs, but were not re-
prescribed intravenous rehydration (even though it is rec-
ommended to start plan C again). In order to address the
lack of specificity of these signs we added two additional
parameters that are also considered as rehydration goals
and/or adverse consequences. We selected time to pass
urine as a more reliable marker of perfusion (as it is speci-
fied or required as an endpoint for management of shock
or hydration status). We also included dysnatraemia, as this
has been used in a number of other clinical trials as a safety
endpoint (defined as a sodium level outside the normal
range (135-145mmol/L) [7]. However, we found, on stored
samples, batch-analysed at the end of the trial, that quite a
number had haemolysis (noted at the time of storage in
– 80 °C freezers) and many had extreme sodium and chlor-
ide values at admission and 8 h which could not be
rechecked for verification. We thus excluded samples with
visual evidence of haemolysis (that also had extreme potas-
sium values) and those with extreme values (sodium > 240
mmol/L and creatinine (< 20mmol/L). However, we do
note that severe hypernatraemia can also cause rhabdo-
myolysis, which would also result in similar findings as
Table 7 Percentage of weight loss at admission (compared to
day 7 weight)
WHO plan C GASTRO slow Total
N 58 57 115
Mean (sd) 6 (6) 7 (6) 7 (6)
Median (IQR) 6 (2, 11) 5 (3, 10) 6 (2, 11)
0–5%, n (%) 24 (41) 28 (42) 52 (45)
5–10%, n (%) 17 (29) 13 (23) 30 (26)
10%, n (%) 17 (29) 16 (28) 33 (29)
Table 8 Signs of dehydration and change in weight
0–5% 5–10% ≥ 10% Total
N 52 30 33 115
Lethargy or unconsciousness, n (%) 42 (80) 24 (80) 29 (88) 95 (83)
Unable to drink, n (%) 38 (73) 24 (80) 25 (76) 87 (76)
Sunken eyes, n (%) 52 (100) 29 (97) 32 (97) 113 (98)
Slow skin pinch, n (%) 32 (62) 20 (67) 27 (82) 79 (69)
Number of symptoms, n (%)
2 11 (21) 6 (20) 3 (9) 20 (17)
3 22 (42) 11 (37) 13 (39) 46 (40)
4 19 (37) 13 (43) 17 (52) 49 (43)
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haemolysis (as well as dark urine) [22]. Discussions with
local trial teams indicated that intravenous access for can-
nulation and blood draws were exceptionally difficult owing
to the extreme volume depletion in many children. More-
over, our finding of exceptionally high sodium level (and
chlorides) in some children is consistent with hypernatrae-
mic dehydration, and with a history of parents rehydrating
children with high-sugar energy fizzy drinks (containing
54–62 g glucose/500 ml). This practice has been reported
on by previously as being a major risk factor for hyperna-
traemic dehydration, as well as young infants receiving only
breast milk [5]. Hypertonic or hypernatraemic dehydration
(defined as a sodium level > 150 mmol/L) occurs when
water loss is much greater than sodium loss and usually
often presents with different clinical signs (‘doughy’ skin in
an irritable child and full fontanelle in an infant) [23] and is
generally recommended to be managed using a separate
slow rehydration protocol [24]. The current WHO rehydra-
tion Plan C protocol recommends that children with severe
isotonic or hypotonic dehydration receive fast rehydration
to restore intracellular sodium and water losses but makes
no recommendations for rehydration of children with
hypernatraemic dehydation. The most conservative esti-
mate, when most haemolysed and extreme values were ex-
cluded, suggests that 26% of children with gastroenteritis in
Eastern Uganda present with hypernatraemic dehydration
(sodium > 150 mmol/L). Nevertheless, outcomes for both
arms were similar with few children developing neuro-
logical complications (one of the risks of hypertonic dehy-
dration) [23, 25] and mortality was much lower that pre-
trial estimates [11]. On the whole sodium levels tended to
normalise by 8- and 24-h in those presenting with hypona-
traemia, normonatraemia and hypernatraemia, with little
difference between the study arms (Fig. 5).
One other challenge we met was incomplete data on time
to pass urine. During the consent process, we asked parents
whether we were able to catheterize children; however, by
24 h, we only had data on 54/122 patients (44%) that had
passed urine despite most having resolved features of dehy-
dration and tolerating oral fluids and feeds (Fig. 3). We sug-
gest that this was due to the fact that parents did not
accept urinary catheterization (not specifically recorded in
the case report form) but consented to enrolment into the
trial. Alternative approaches to an 8-hourly assessment of
urine output included estimating urine output from weigh-
ing nappies (diapers) or the use of urine collections bags
(specifically in females) were not viable options in children
with on-going diarrhoeal losses.
One hypothesis, to explain the excess mortality and mode
of death observed in the FEAST trial is that cardiovascular
Fig. 5 Mean (95% CI) of sodium levels over 24 h by study arm in children categorised as hyponatraemic, normomatraemic and hypernatraemic
at admission
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collapse may occur as a result of right atrial stretch follow-
ing aggressive fluid loading, and could be predicted by myo-
cardial performance indices, raised ANP (atrial natriuretic
peptide) [26] and subsequent urinary sodium excretion.
ANP is a cardiac hormone that is released in response to
atrial stretch [27]. In an ovine model of sepsis, a 14-fold rise
in ANP levels was seen in experimental endotoxaemia and
further rise with fluid resuscitation [28] but not in the con-
trol (no bolus arm). However, in that study, the rise was
transient and peaked just after volume loading with a fluid
bolus before declining. In contrast, the ANP profile in this
cohort of dehydrated children rose from admission to 8 h
and remained persistently high at day 7.
BNP is released in response to ventricular stretch and
has been shown to have diuretic, natriuretic and vasodila-
tor properties in published literature [16] . A study by
Westerlind et al. (2008), reported the highest ANP and
BNP values in children with systolic dysfunction and vol-
ume overload [29]. It has also been reported to be high in
conditions such as sepsis [30, 31]. Price et al. (2006) re-
ported a higher risk of hospitalisation and mortality in
children with systolic dysfunction and elevated BNP levels
[32]. In this cohort, BNP levels were highest at admission
in both groups with severe dehydration, which was not
accounted for by high creatinine level in this with high
BNP, then decreased over the first 8-h despite fluid admin-
istration, but later increased at 24 h. Troponin I is a
marker of cardiac muscle injury independent of volume
status. Soldin et al. (1999) reported higher levels of tropo-
nin in children under-1 year [33]. The levels of troponin
were normal and comparable in both groups. Whilst there
was a rise in troponin following fluid administration at 8
h, 24 h and day 7, values were still within normal ranges
and did not indicate cardiac injury.
The strength of our trial is that it includes an unse-
lected population (except the exclusion of children with
severe malnutrition, who are managed under a separate
guideline [6, 34]), good adherence to protocol, and com-
pleteness of follow up. These factors plus the close clin-
ical monitoring of children may have resulted in the low
overall mortality in contrast to previous reports [11].
The low mortality (3.3%) together with the lack of other
volume-specific complications indicates that slower re-
hydration is at least as safe as current Plan C.
The limitations include our inability to show surrogates
of rehydration (time to pass urine in many of the children
as routine catheterization was impractical and not accept-
able to parents) and sodium endpoint (dysnatraemia at 8
h) was compromised by the high number of children with
high sodium levels on admission, which we were not able
to repeat as these were not done real-time but on batch
processing of stored plasma at the end of the trial. Further
observational studies, in Uganda in particular, are required
to verify, using fresh sample analysis, whether children
admitted with severe gastroenteritis frequently have
hypernatraemic dehydration and whether these children
had a history of taking sugary drinks. If true, then there
would be a public health imperative to ensure populations
are aware of and understand the risks of such practices.
Conclusions
In this phase II trial, we have shown that slow rehydration
over 8 h is as safe as WHO Plan C resulting in similar
surrogate markers of patient outcome (resolution of dehy-
dration signs, time to tolerate oral fluids and time to dis-
charge) and no evidence of increase of adverse events
(including mortality and fluid-volume related event).
Training throughout the trial was required to reinforce
adherence to the more complicated 2-step WHO plan C
protocol. We suggest further large multicentre trials
should test slow rehydration, as per GASTRO protocol,
against Plan C with mortality as an endpoint.
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